Survival of pediatric acute lymphoblastic leukemia
(ALL) continues to improve over last three decades. Current survival
rates in advanced centers are nearly 90% [1]. In India, the overall
survival in pediatric ALL varies from 46-80% [2]. Most improvements in
ALL are not due to advent of new medicines but secondary to treatment
refinements, which also include reduction of therapy for low-risk
patients thereby reducing toxic mortality [3].
Most children with ALL attain a morphologic remission
after induction chemotherapy. Many children will eventually relapse due
to residual leukemic cells that are below the limits of detection using
conventional morphologic assessment. This residual leukemia is termed as
minimal residual disease (MRD), and can be evaluated using multicolor
flowcytometry or polymerase chain reactions [4].
Age at diagnosis, initial white blood cell count and
cytogenetics are often used to stratify children into standard and
high-risk ALL to ascertain the appropriate treatment protocol. It is
imperative to revisit the chemotherapy protocol based on the response to
initial therapy. MRD detection is an important diagnostic modality in
this regard [5]; children with high MRD in either risk groups do not do
well.
A large data of 7,430 children with ALL demons-trated
that 5-year disease-free survival was significantly higher among
MRD-negative compared to MRD-positive children (89% vs 72%). The
MRD-positive children are candidates for further intensification of
therapy and consideration of allogenic bone marrow transplantation. MRD
also trumped morphologic evaluation of bone marrow on day-14.
Disease-free survival was similar if children became MRD-negative on
day-29. These results suggest that MRD status using a threshold of 0.01
percent at the end of induction obviates the need for bone marrow
analysis at day-14 [6].
At the same time there are a lot of children with
standard risk ALL who are MRD-negative at defined time points. These are
the children for possible reduction in intensity of therapy. A large
trial of over 3000 children and young adults randomized MRD-negative
patients to receive two or one delayed intensification therapies. Both
arms had similar event-free survival (94.4% vs 95.5%), overall
survival and rate of relapse at five years [7]. Thus, MRD may be used to
de-escalate therapy in certain children. Children’s Oncology Group (COG)
data suggest that 50% of relapses still occur in children with standard
risk B-ALL who were MRD-negative [8]. We therefore need to be cautious
in de-escalating therapies in MRD-negative children till further data
emerges.
Bommannan, et al. [9] report their data on
mid-induction peripheral blood MRD in a small cohort of 40 children with
a follow-up reasonable enough to pick at least early relapses. It is
heartening to see few things stand out from their data. We always talk
about resource constraints in our country. Here, we have six-color
flowcytometry available for MRD evaluation. Disease load is certainly
more in bone marrow compared to peripheral blood suggesting that bone
marrow continues to remain gold standard for disease evaluation. They
report high rates (62.5%) of MRD-positivity in bone marrow on day-15.
This is a high proportion and signifies delayed blast clearance from
bone marrow, or using lower threshold of 0.01% as positivity. Children
who were MRD-negative did not experience any relapses and few relapses
in MRD-positive patients probably due to early analysis. It is possible
that many of D15+ patients would have become MRD-negative by D30 of
induction chemotherapy. It is quite possible that more D15 data emerges
with different cut-off for us to decide in terms of escalation or
de-escalation of therapy.
The interpretation of MRD is complicated and must
take into account the timing of assessment, level of MRD and sensitivity
of test being used. The main reason to perform MRD assessment is to
assess response and be able to act on the information like day-30 of
induction when treatment phase changes. Therefore, timing of MRD
assessment is crucial. MRD cut-off of day-30 is not relevant for day-15
analysis.
Most ALL protocols are made with inputs from lot of
research. Each protocol will have defined a different time point for MRD
analysis and a different cut-off. We should not mix and match protocols
for these analyses. Rectifications are inbuilt into current protocols
based on MRD analysis. Another interesting aspect was the message that
one should stick to protocol. As in this study, children with high-risk
ALL (after addition of daunorubicin) did as well as their standard risk
counterparts in terms of response to therapy and lowering of MRD [9].
This study provides relevant data amongst Indian children with ALL, and
suggests a good correlation between peripheral blood and bone marrow
MRD. A long term follow-up of this cohort will generate data, which will
make us wiser.
1. Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M,
Biondi A, et al. Childhood acute lymphoblastic leukemia: Progress
through collaboration. J Clin Oncol. 2015; 33:2938-48.
2. Arora RS, Arora B. Acute leukemia in children: A
review of the current Indian data. South Asian J Cancer. 2016; 5:155-60.
3. Trehan A, Bansal D, Varma N, Vora A. Improving
outcome of acute lymphoblastic leukemia with a simplified protocol:
Report from a tertiary care center in North India. Pediatr Blood Cancer.
2016;Oct 20:doi: 10.1002/pbc.26281
4. Setiadi A, Owen D, Tsang A, Milner R, Vercauteren
S. The significance of peripheral blood minimal residual disease to
predict early disease response in patients with B-cell acute
lymphoblastic leukemia. Int J Lab Hematol. 2016;38:527-34.
5. Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha
S, Cheng C, et al. Clinical impact of minimal residual disease in
children with different subtypes of acute lymphoblastic leukemia treated
with Response-Adapted therapy. Leukemia. 2016;Sep 13:doi:
10.1038/leu.2016. 234. [Epub ahead of print]
6. Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA,
Larsen E, et al. Assessment of end induction minimal residual
disease (MRD) in childhood B precursor acute lymphoblastic leukemia
(ALL) to eliminate the need for day 14 marrow examination: A Children’s
Oncology Group study (abstract 10001). J Clin Oncol. 2013;31:613s.
7. Vora A, Goulden N, Wade R, Mitchell C, Hancock J,
Hough R, et al. Treatment reduction for children and young adults
with low-risk acute lymphoblastic leukaemia defined by minimal residual
disease (UKALL 2003): A randomised controlled trial. Lancet Oncol.
2013;14:199-209.
8. Borowitz MJ, Devidas M, Hunger SP, Bowman
WP, Carroll AJ, Carroll WL, et al; Children’s Oncology Group.
Clinical significance of minimal residual disease in childhood acute
lymphoblastic leukemia and its relationship to other prognostic factors:
a Children’s Oncology Group study. Blood. 2008;111:5477-85.
9. Bommannan K, Sachdeva MU, Varma N, Bose P, Bansal
D. Role of mid-induction peripheral blood minimal residual disease
detection in pediatric B-lineage acute lymphoblastic leukemia. Indian
Pediatr. 2016;53:1065-8.